Evidence map›Paper›PMID 35177071›Full record

ReviewWorld journal of surgical oncology2022

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.

Xiaoying Hou, Cong Du, Ligong Lu, Shengtao Yuan, Meixiao Zhan, Pengtao You, Hongzhi Du

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Crosstalk between autophagy and ferroptosis in liver diseases (Review).International journal of molecular medicine · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoying Hou *Wuhan Institutes of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan, 430056, China.
Cong Du *Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510620, China.
Ligong LuZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, 519000, China.
Shengtao YuanJiangsu Key Laboratory of Drug Screening, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 2100 9, China.
Meixiao ZhanZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, 519000, China. zhanmeixiao1987@126.com.
Pengtao YouSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China. tptyou@hbtcm.edu.cn.
Hongzhi DuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China. dhz3163@hbtcm.edu.cn.

Funding

National Natural Science Foundation of China 81903845Postdoctoral Research Foundation of China 2020M670599
6 · The paper itself

Abstract

backgroundAs reported, preclinical animal models differ greatly from the human body. The evaluation model may be the colossal obstacle for scientific research and anticancer drug development. Therefore, it is essential to propose efficient evaluation systems similar to clinical practice for cancer research. MAIN BODY: While it has emerged for decades, the development of patient-derived xenografts, patient-derived organoid and patient-derived cell used to be limited. As the requirements for anticancer drug evaluation increases, patient-derived models developed rapidly recently, which is widely applied in basic research, drug development, and clinical application and achieved remarkable progress. However, there still lack systematic comparison and summarize reports for patient-derived models. In the current review, the development, applications, strengths, and challenges of patient-derived models in cancer research were characterized.

conclusionPatient-derived models are an indispensable approach for cancer research and human health.

Indexed as

Antineoplastic AgentsNeoplasmsAnimalsDisease Models, AnimalHeterograftsHumansOrganoidsXenograft Model Antitumor AssaysAntineoplastic AgentsNCI-60Patient-derived cell (PDC)Patient-derived modelPatient-derived organoid (PDO)Patient-derived xenograft (PDX)

Identifiers

PMID35177071
PMCPMC8851816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.